Publicador de contenidos

Investigación e Innovación Programas

WHIP3TB

Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals

Duración
June 2017 - September 2019
Coordinador
Alberto García-Basteiro
Financiadores
USAID / KNCV
Página web
https://clinicaltrials.gov/ct2/show/NCT02980016

This study is a parallel, two part, open label, individually randomized, pragmatic clinical trial to assess different alternatives to prevent tuberculosis (TB) among HIV-positive individuals. Part A compares a single round of weekly high dose rifapentine plus isoniazid for three months (3HP) to six months of daily isoniazid (6H). Part B compares periodic 3HP (p3HP) to a single round of 3HP.

This clinical trial aims to improve (shorten and simplify) currently available tools to prevent tuberculosis among HIV-positive individuals. The current recommendation is to provide single dose isoniazid daily during 6 months among HIV-positive individuals in whom TB disease has been ruled out. However, the implementation of this recommendation is limited in high burden countries, mostly due to adherence hurdles derived from such lengthy prophylaxis.

The study aims to enroll 4000 participants from three different countries: South Africa, Mozambique and Ethiopia. In Mozambique, the only participating site will be the Centro de Investigação em Saude de Manhiça (CISM).

Total funding

1.6 million Euros

 

Nuestro equipo

Principal Investigator

  • Alberto García Basteiro
    Alberto García Basteiro

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

GAMA

Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

PreFIT

Predicting the Future: Incipient Tuberculosis

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

END-VOC

ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)

TwinAir

Digital Twins Enabled Indoor Air Quality Management for Healthy Living

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias